TABLE 6.
Biomarkers as outcome measures in Phase 2 and Phase 3 disease‐modifying therapies trials (ClinicalTrials.gov accessed February 27, 2020)
| N of trials (%) | ||
|---|---|---|
| Biomarker | Phase 2 | Phase 3 |
| CSF amyloid | 15 (25%) | 10 (48%) |
| CSF tau | 17 (28%) | 9 (43%) |
| FDG‐PET | 7 (11%) | 1 (5%) |
| Vmri | 8 (13%) | 8 (38%) |
| Plasma amyloid | 7 (11%) | 2 (10%) |
| Plasma tau | 2 (3%) | 1 (5%) |
| Amyloid PET | 5 (8%) | 7 (33%) |
| Tau PET | 4 (7%) | 3 (14%) |
Abbreviations: CSF, cerebrospinal fluid; FDG, fluorodeoxyglucose; PET, positron emission tomography; vMRI, volumetric magnetic resonance imaging.